Design and baseline results of the monosialoganglioside early stroke trial. The EST Study Group - PubMed (original) (raw)

Clinical Trial

Design and baseline results of the monosialoganglioside early stroke trial. The EST Study Group

W A Rocca et al. Stroke. 1992 Apr.

Abstract

Background and purpose: The Early Stroke Trial is a randomized, placebo-controlled, double-masked, multicenter study to assess the safety and efficacy of monosialoganglioside in patients who have suffered an ischemic stroke of the cerebral hemispheres.

Methods: Only patients who could be evaluated and treated within 5 hours after the onset of stroke were considered; within each center, subjects were stratified by age, sex, and clinical severity. Patients were randomly allocated to receive a specified sequence of intravenous and intramuscular doses of either monosialoganglioside or identical-appearing placebo for 21 days. Patients were followed up for 4 months after randomization. Neurological status was measured primarily by using the Canadian Neurological Scale. After assessing the effect of treatment on survival, the principal measure of efficacy will be the change in neurological status between baseline and the 4-month follow-up among survivors.

Results: Sixteen clinical centers, 15 in Europe and one in North America, entered a total of 792 eligible patients during a 36-month recruitment period (from May 1987 to April 1990). In our series there were more men than women, and the relative frequency of patients increased with advancing age. The most frequently associated cardiovascular conditions were hypertension, atrial fibrillation, and peripheral vascular disease. Approximately 46% of the patients were admitted to a hospital within 1 hour and 81%, within 2 hours after the onset of stroke. About 22% first received the study treatment within 3 hours and 57%, within 4 hours.

Conclusions: This study demonstrates the feasibility of large-scale trials with the onset of treatment within 5 hours after an ischemic stroke.

PubMed Disclaimer

Cited by

Trends and future developments in the pharmacological treatment of acute ischaemic stroke.
del Zoppo GJ, Wagner S, Tagaya M. del Zoppo GJ, et al. Drugs. 1997 Jul;54(1):9-38. doi: 10.2165/00003495-199754010-00002. Drugs. 1997. PMID: 9211077 Review.
Embryonic tissue differentiation in Caenorhabditis elegans requires dif-1, a gene homologous to mitochondrial solute carriers.
Ahringer J. Ahringer J. EMBO J. 1995 May 15;14(10):2307-16. doi: 10.1002/j.1460-2075.1995.tb07225.x. EMBO J. 1995. PMID: 7774589 Free PMC article.
The topology of the brown adipose tissue mitochondrial uncoupling protein determined with antibodies against its antigenic sites revealed by a library of fusion proteins.
Miroux B, Frossard V, Raimbault S, Ricquier D, Bouillaud F. Miroux B, et al. EMBO J. 1993 Oct;12(10):3739-45. doi: 10.1002/j.1460-2075.1993.tb06051.x. EMBO J. 1993. PMID: 7691596 Free PMC article.
Gangliosides for acute ischaemic stroke.
Candelise L, Ciccone A. Candelise L, et al. Cochrane Database Syst Rev. 2000;2001(2):CD000094. doi: 10.1002/14651858.CD000094. Cochrane Database Syst Rev. 2000. PMID: 10796297 Free PMC article. Updated. Review.
The Dark Side of Sphingolipids: Searching for Potential Cardiovascular Biomarkers.
Di Pietro P, Izzo C, Abate AC, Iesu P, Rusciano MR, Venturini E, Visco V, Sommella E, Ciccarelli M, Carrizzo A, Vecchione C. Di Pietro P, et al. Biomolecules. 2023 Jan 13;13(1):168. doi: 10.3390/biom13010168. Biomolecules. 2023. PMID: 36671552 Free PMC article. Review.

Design and baseline results of the monosialoganglioside early stroke trial. The EST Study Group - PubMed (original) (raw)